Nonalcoholic Fatty Liver Disease Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease

被引:126
作者
Polyzos, Stergios A. [1 ]
Kountouras, Jannis [1 ]
Zavos, Christos [1 ]
Deretzi, Georgia [1 ]
机构
[1] Aristotle Univ Thessaloniki, Ippokrat Hosp, Dept Med, Med Clin 2, GR-54006 Thessaloniki, Greece
关键词
insulin resistance; metabolic syndrome; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; treatment; VITAMIN-E; INSULIN-RESISTANCE; URSODEOXYCHOLIC ACID; METABOLIC SYNDROME; STEATOHEPATITIS; RISK; PNPLA3; PIOGLITAZONE; ATORVASTATIN; COMBINATION;
D O I
10.1097/MCG.0b013e31824587e0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) has emerged as a significant public health problem. Besides the liver, NAFLD is also associated with increased cardiovascular and overall morbidity and mortality. NAFLD warrants intensive research, because no treatment has been established as yet. This may be partly attributed to the fact that the majority of the relative clinical trials have a monotherapeutic direction. However, the multifactorial pathogenesis of NAFLD may probably direct clinical trials to a combined therapeutic approach. The aim of this review is to provide a description of the multifactorial pathogenesis of NAFLD and type II diabetes mellitus-NAFLD interplay, and to summarize the therapeutic trials focusing on the combined NAFLD treatment, providing a link between the multiple-hit pathogenesis and the multimodal treatment of NAFLD patients. A diabetes-like therapeutic approach for NAFLD is finally proposed.
引用
收藏
页码:272 / 284
页数:13
相关论文
共 89 条
  • [1] Abel T, 2009, MED SCI MONITOR, V15, pMS6
  • [2] Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study
    Adams, Leon A.
    Harmsen, Scott
    St Sauver, Jennifer L.
    Charatcharoenwitthaya, Phunchai
    Enders, Felicity B.
    Therneau, Terry
    Angulo, Paul
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (07) : 1567 - 1573
  • [3] American Diabetes Association, 2011, DIABETES CARE S1, V34, P4
  • [4] Effect of Atorvastatin, Vitamin E and C on Nonalcoholic Fatty Liver Disease: Is the Combination Required?
    Arendt, Bianca M.
    Allard, Johane P.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (01) : 78 - 80
  • [5] Thiazolidinediones for the Treatment in NASH Sustained Benefit After Drug Discontinuation?
    Argo, Curtis K.
    Iezzoni, Julia C.
    Al-Osaimi, Abdullah M. S.
    Caldwell, Stephen H.
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2009, 43 (06) : 565 - 568
  • [6] Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
    Athyros, Vasilios G.
    Mikhailidis, Dimitri P.
    Didangelos, Triandafillos P.
    Giouleme, Olga I.
    Liberopoulos, Evangelos N.
    Karagiannis, Asterios
    Kakafika, Anna I.
    Tziomalos, Konstantinos
    Burroughs, Andrew K.
    Elisaf, Moses S.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) : 873 - 883
  • [7] Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
    Athyros, Vasilios G.
    Tziomalos, Konstantinos
    Gossios, Thomas D.
    Griva, Theodora
    Anagnostis, Panagiotis
    Kargiotis, Konstantinos
    Pagourelias, Efstathios D.
    Theocharidou, Eleni
    Karagiannis, Asterios
    Mikhailidis, Dimitri P.
    [J]. LANCET, 2010, 376 (9756) : 1916 - 1922
  • [8] Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis
    Balmer, Maria Luisa
    Siegrist, Kathrin
    Zimmermann, Arthur
    Dufour, Jean-Francois
    [J]. LIVER INTERNATIONAL, 2009, 29 (08) : 1184 - 1188
  • [9] Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)
    Bellentani, Stefano
    Marino, Mariano
    [J]. ANNALS OF HEPATOLOGY, 2009, 8 : S4 - S8
  • [10] NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages
    Bieghs, Veerle
    Rensen, Patrick C. N.
    Hofker, Marten H.
    Shiri-Sverdlov, Ronit
    [J]. ATHEROSCLEROSIS, 2012, 220 (02) : 287 - 293